Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and KemPharm (NASDAQ:KMPH – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Profitability

This table compares Abliva AB (publ) and KemPharm's net margins, return on equity and return on assets.

This is a summary of current recommendations and price targets for Abliva AB (publ) and KemPharm, as provided by MarketBeat.com.

KemPharm has a consensus price target of $11.00, indicating a potential upside of 130.13%. Given KemPharm's higher possible upside, analysts plainly believe KemPharm is more favorable than Abliva AB (publ).

Insider and Institutional Ownership

32.4% of KemPharm shares are held by institutional investors. 1.1% of KemPharm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Abliva AB (publ) and KemPharm's revenue, earnings per share and valuation.

Abliva AB (publ) has higher earnings, but lower revenue than KemPharm.

Summary

KemPharm beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.

About Abliva AB (publ) (Get Rating)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

About KemPharm (Get Rating)

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.